SMARCA4 and non-small cell lung carcinoma: Finally, the impact of BRG1-LOF and its broad epigenome reprograming effects on therapeutic vulnerabilities of NSCLC to a library of epigenetic drugs were investigated in vitro, and the most promising drug combinations were tested in vivo.